AgomAb Therapeutics NV Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	86.42	171.46
Short-Term Investments	30.1	-
Cash & Short-Term Investments	116.51	171.46
Cash Growth	-32.05%	-
Other Current Assets	4.72	2.39
Total Current Assets	121.24	173.85
Net Property, Plant & Equipment	1.59	1.99
Other Intangible Assets	20.11	20.11
Goodwill	8.61	8.61
Long-Term Investments	0.01	0.01
Other Long-Term Assets	2.15	1.79
Total Assets	153.71	206.36
Accounts Payable	10.27	8.05
Accrued Expenses	1.55	0.8
Current Portion of Leases	0.25	0.27
Other Current Liabilities	6.53	-
Total Current Liabilities	18.59	9.13
Long-Term Leases	1.01	1.27
Other Long-Term Liabilities	3.21	7.88
Total Long-Term Liabilities	4.22	9.15
Total Liabilities	22.8	18.28
Common Stock	223.07	223.07
Additional Paid-in Capital	90.51	85.16
Accumulated Other Comprehensive Income	-0.97	-0.97
Retained Earnings	-181.71	-119.18
Shareholders' Equity	130.9	188.08
Total Liabilities & Equity	153.71	206.36
Total Debt	1.25	1.55
Net Cash (Debt)	115.26	169.91
Net Cash Growth	-32.17%	-
Net Cash Per Share	213.00	314.00
Book Value	130.9	188.08
Book Value Per Share	241.91	347.57
Tangible Book Value	102.18	159.36
Tangible Book Value Per Share	188.83	294.50

SEC Filings: 10-K · 10-Q